Search Within

Robert Motzer

  1. "Advanced Practice Providers"
Formats
  1. Meeting Abstract (13)
  2. Journal Article (7)
Groups
  1. Advanced Practice Providers (20)
  2. Department of Medicine (20)
  3. Genitourinary Oncology Service (20)
  4. Solid Tumor Oncology Division (20)
  5. Surgery (18)
  6. Urology (18)

More Groups

People
  1. Darren Feldman (17)
  2. George Bosl (12)
  3. Sujata Patil (12)
  4. Joel Sheinfeld (11)
  5. Dean Bajorin (10)
  6. Maryann Carousso (9)

More People

Years
  1. 2021 (2)
  2. 2019 (2)
  3. 2018 (2)
  4. 2017 (3)
  5. 2016 (2)
  6. 2015 (1)

More Years

Publications
  1. Journal of Clinical Oncology (8)
  2. European Urology Focus (2)
  3. BJU International (1)
  4. Biology of Blood and Marrow Transplantation (1)
  5. Cancer (1)
  6. Clinical Genitourinary Cancer (1)

More Publications

Publishers
  1. American Society of Clinical Oncology (8)
  2. Elsevier B.V. (2)
  3. Elsevier Inc. (2)
  4. Wiley Blackwell (2)
  5. Elsevier Science, Inc. (1)
  6. Nature Publishing Group (1)

More Publishers

Results (20)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Paclitaxel, ifosfamide, and cisplatin efficacy for first-line treatment of patients with intermediate- or poor-risk germ cell tumors
    Journal Article

    Feldman, D. R.; Hu, J.; Dorff, T. B.; Lim, K.; Patil, S.; Woo, K. M.; Carousso, M.; Hughes, A.; Sheinfeld, J.; Bains, M.; more...
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • Phase I/II trial of paclitaxel with ifosfamide followed by high-dose paclitaxel, ifosfamide, and carboplatin (TI-TIC) with autologous stem cell reinfusion for salvage treatment of germ cell tumors
    Journal Article

    Feldman, D. R.; Glezerman, I.; Patil, S.; Van Alstine, L.; Bajorin, D. F.; Fischer, P.; Hughes, A.; Sheinfeld, J.; Bains, M.; Reich, L.; more...
    Clinical Genitourinary Cancer (2015)

    Fulltext@MSK | Save
  • Acute changes in endothelial function with cisplatin among germ cell tumor (GCT) patients (Pts)
    Meeting Abstract

    Feldman, D. R.; Jacobsen, E. P.; Woo, K.; Steingart, R.; Fleisher, M.; Patil, S.; Carousso, M.; Laguerre, S.; Morales, T. D.; Sheinfeld, J.; more...
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • Phase I/II study of paclitaxel plus ifosfamide followed by high-dose paclitaxel, ifosfamide, and carboplatin with autologous stem cell reinfusion for salvage treatment of germ cell tumors
    Meeting Abstract

    Feldman, D. R.; Glezerman, I.; Patil, S.; Van Alstine, L.; Bajorin, D. F.; Fischer, P.; Hughes, A.; Sheinfeld, J.; Bains, M.; Reich, L.; more...
    Biology of Blood and Marrow Transplantation (2014)

    Fulltext@MSK | Save
  • Phase II trial of paclitaxel, ifosfamide, and cisplatin (TIP) for previously untreated patients (pts) with intermediate- or poor-risk germ cell tumors (GCT)
    Meeting Abstract

    Feldman, D. R.; Hu, J.; Dorff, T. B.; Patil, S.; Van Alstine, L. J.; Momen, L.; Carousso, M.; Hughes, A.; Snively-Solomon, J.; Ketchens, C.; more...
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save
  • Phase I/II study of paclitaxel plus ifosfamide (TI) followed by high-dose paclitaxel, ifosfamide, and carboplatin (TIC) with autologous stem cell transplant (ASCT) for salvage treatment of germ cell tumors (GCT)
    Meeting Abstract

    Jia, X.; Feldman, D. R.; Glezerman, I.; Van Alstine, L. J.; Bajorin, D. F.; Fischer, P.; Hughes, A.; Sheinfeld, J.; Bains, M. S.; Reich, L.; more...
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save
  • Paclitaxel, ifosfamide, and cisplatin (TIP) efficacy for first-line treatment of patients (pts) with intermediate- or poor-risk germ cell tumors (GCT)
    Meeting Abstract

    Feldman, D. R.; Hu, J.; Dorff, T. B.; Patil, S.; Van Alstine, L. J.; Momen, L.; Carousso, M.; Hughes, A.; Snively-Solomon, J.; Ketchens, C.; more...
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save
  • Progression-free and overall survival in patients with relapsed/refractory germ cell tumors treated with single-agent chemotherapy: Endpoints for clinical trial design
    Journal Article

    Feldman, D. R.; Patil, S.; Trinos, M. J.; Carousso, M.; Ginsberg, M. S.; Sheinfeld, J.; Bajorin, D. F.; Bosl, G. J.; Motzer, R. J.
    Cancer (2012)

    Fulltext@MSK | Save
  • Progression-free survival (PFS) as a new endpoint for designing phase II trials in patients with refractory germ cell tumors (GCT)
    Meeting Abstract

    Feldman, D. R.; Patil, S.; Trinos, M. J.; Carousso, M.; Ginsberg, M. S.; Sheinfeld, J.; Bajorin, D. F.; Bosl, G. J.; Motzer, R. J.
    Journal of Clinical Oncology (2010)

    Fulltext@MSK | Save
  • Phase II trial of sunitinib in patients with relapsed or refractory germ cell tumors
    Journal Article

    Feldman, D. R.; Turkula, S.; Ginsberg, M. S.; Ishill, N.; Patil, S.; Carousso, M.; Bosl, G. J.; Motzer, R. J.
    Investigational New Drugs (2010)

    Fulltext@MSK | Save